ASH: J&J's fast-growing Darzalex lines up for second front-line myeloma OK

Johnson & Johnson’s Darzalex made multiple myeloma history in May when it became the first monoclonal antibody to score an FDA approval in newly diagnosed patients. And now, armed with a new batch of data, it’s looking for a repeat.